Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14.00 to 16:00.
Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After an FDA approval, the large market for patient monitoring will become available.
We therefore invite you to a virtual Capital Markets Day on 11 May 2020 at 2:00 to 4:00 pm.
Link will be found at Biovicas website: www.biovica.com/biovica/investor-relations/events/ questions can be sent to firstname.lastname@example.org
At the Capital Markets Day Robert Dann, SVP Marketing and US Business and Henrik Winther SVP Business Development, will present the plan for the market launch of DiviTum®, oncologist Samuel Rotstein from Karolinska Hospital will present his views on the value DiviTum® could bring patients and the healthcare system, and CEO Anders Rylander will give an update on Biovica’s current situation.
For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
In the event of contradictions or differences between the Swedish press release and this English version the Swedish text will prevail.
Biovica – Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica’s assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum® is monitoring of treatment for patients with metastatic breast cancer. Biovica’s vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica’s shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company’s Certified Adviser, email@example.com, +46 8 528 00 399. For more information please visit: www.biovica.com.